[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"silent-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:silent-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,76,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100558028","intraoperative-diagnosis-of-neurocognitive-complications-via-electroencephalographic-analysis-100558028",false,"NCT06545786","Intraoperative Diagnosis of Neurocognitive Complications Via Electroencephalographic Analysis","Intraoperative Diagnosis of Neurocognitive Complications Via Electroencephalographic (IDEA Network)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Scheduled non-cardiac surgery of intermediate or high risk\n* General anesthesia using inhalational anesthetics\n* Informed consent from the patient to participate in the study\n\nExclusion Criteria:\n\n* Preoperative MMSE score less than 20 points\n* History of any mental illness\n* Use of psychotropic drugs within 1 month prior to inclusion in the study\n* Presence of neuromuscular diseases\n* Neurosurgical procedures\n* Inability to undergo preoperative testing for any reason","ALL","18 Years",{"count":19,"type":20},265,"ESTIMATED","OBSERVATIONAL","Postoperative neurocognitive disorders (PND) are serious and common complications after surgery, especially in elderly patients. These disorders can affect cognitive functions for years, deteriorating quality of life and increasing hospital stays and medical costs. Diagnosing PND is challenging due to their varied manifestations, such as memory and attention problems, and the lack of standardized criteria and biomarkers.\n\nOne well-studied form of PND is postoperative delirium (POD). According to the ICD-10, POD is an organic cerebral syndrome characterized by disturbances in consciousness, attention, perception, and other cognitive functions. Researchers suggest that POD development involves a combination of predisposing and precipitating factors.\n\nElectroencephalography (EEG) has been used in anesthesiology to assess anesthesia depth and intraoperative awareness. Modern EEG analysis methods, like spectral analysis, offer new ways to evaluate patients' neurophysiological states. Studies show that EEG monitoring can predict complications such as intraoperative stroke and delirium, particularly in cardiothoracic and neurosurgical operations.\n\nThe relationship between EEG patterns and POD is not well understood. Specific EEG patterns may indicate the risk of POD, aiding in the identification of risk factors and prevention methods. This could help anesthesiologists and surgeons optimize their approaches, reducing the risk of cognitive complications.",[24,25,26,27,28],"Surgery","Postoperative Delirium","Anesthesia","Silent Stroke","Emergence Delirium",[30,26,25,27,28],"Non-cardiac surgery","RECRUITING","2025-04-04",{"date":34,"type":35},"2025-04-08","ACTUAL",{"date":37,"type":35},"2024-09-25",{"date":39,"type":20},"2027-08-20",{"name":41,"class":42},"Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100491894","prevalence-of-attributable-etiology-and-modifiable-stroke-risk-factors-in-patients-with-covert-brain-infarctions-100491894","NCT05685069","Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions","Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions (CBI-registry)","CBI-Registry","Inclusion Criteria:\n\n* Any clinically silent ischemic lesions of the brain parenchyma detected on neuroimaging defined according to established criteria as either:\n\n  * DWI positive lesions: Focus of restricted diffusion (high DWI signal and low ADC value) occurring in either white or gray matter, located in the cerebrum, cerebellum, or brain stem AND not satisfying the diagnostic criteria for MS OR\n  * Cavitatory Lesions: ≥ 3 mm in size that follow CSF on all sequences that are slit or wedge shaped with an irregular margin AND NOT longitudinally aligned with perforating vessels or with a multiple, bilateral symmetrical distribution OR\n  * T2W hyperintense\u002FT1W hypointense lesions: Focal lesion with high T2W signal and low T1W signal that have prior evidence of restricted diffusion; OR present within cortical gray matter or deep gray matter nuclei OR a lesion that is new, compared with an MRI performed within 3 months OR T2W hyper\u002FT1W hypointense lesions in the white matter, which are discontinuous but associated with the classic confluent periventricular T2 intense change of leukoaraiosis (Fazekas ≥2) AND NOT satisfying the diagnostic criteria for MS or with a significant patient history of severe trauma, radiation, drug toxicity, or carbon monoxide poisoning\n* Informed Consent as documented by signature by patient or legally authorized representative\n\nExclusion Criteria:\n\n* Projected life expectancy of less than 2 years,\n* Contraindication to MRI,\n* Patients with a history of symptoms compatible with an AIS\u002FTIA attributable to the lesion observed, covert neurological deficits are allowed,\n* Patient is already included in another clinical trial that will affect the objectives of this study,\n* Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his\u002Fher own wishes correspondingly,\n* Women who are pregnant or breast feeding or intention to become pregnant during the course of the study,\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,\n* Contraindications to any of the routine procedures, e.g. inability to obtain neurovascular ultrasound examination,\n* Known or suspected non-compliance, drug or alcohol abuse","16 Years",{"count":54,"type":20},230,"The CBI registry is a prospective, interdisciplinary, multimodal observational registry of patients with covert brain infarction. Methods: A standardized workup in analogy to manifest ischemic stroke including cerebral MRI, long-term rhythm monitoring (3 x 7 days ECG), echocardiography, laboratory work-up and risk factor assessment as well as noninvasive angiography of the cervical and intracranial arteries will be performed.",[27,57,58,59,60,61],"Silent Cerebral Infarct","Covert Brain Infarct","Covert Brain Infarction","Lacune","Silent Brain Infarction",[63,64,65],"Covert brain infarction","Covert cerebrovascular disease","Ischemic stroke","2024-11-12",{"date":68,"type":35},"2024-11-14",{"date":70,"type":35},"2019-03-01",{"date":72,"type":20},"2026-08-31",{"name":74,"class":42},"Insel Gruppe AG, University Hospital Bern",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100397008","incidence-of-silent-atrial-fibrillation-in-patients-with-clinically-silent-brain-ischemic-lesions-100397008","NCT04449523","Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions","Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions (SILENT2)","SILENT2","Inclusion Criteria:\n\n* Age\n\n  * ≥ 65 years\n  * ≥ 50 years AND one the following:\n\n    * NT-proBNP \\>400 pg\u002FmL\n    * Left atrial ventricular index \\>42 ml\u002Fm2 or left atrial diameter \\>46 mm\n    * Covert infarctions with cortical involvement in more than one vascular territory (left carotid territory, right carotid territory, vertebrobasilar territory)\n* Written informed Consent\n* Any clinically silent ischemic lesions of the brain parenchyma detected on neuroimaging defined according to established criteria as either:\n\n  * Diffusion weighted imaging (DWI) positive lesions: Focus of restricted diffusion (high DWI signal and low apparent diffusion coefficient value) occurring in either white or gray matter, located in the cerebrum, cerebellum, or brain stem AND not satisfying the diagnostic criteria for multiple sclerosis OR\n  * Cavitatory Lesions: ≥ 3 mm in size that follow cerebro-spinal fluid on all sequences that are slit or wedge shaped with an irregular margin AND NOT longitudinally aligned with perforating vessels or with a multiple, bilateral symmetrical distribution OR\n  * T2 weighted (T2W) hyperintense\u002FT1 weighted (T1W) hypointense lesions:\n\n    * Focal lesion with high T2W signal and low T1W signal that have prior evidence of restricted diffusion; OR\n    * Present within cortical gray matter or deep gray matter nuclei OR\n    * A lesion that is new, compared with an MRI performed within 3 months OR\n    * T2W hyper\u002FT1W hypointense lesions in the white matter, which are discontinuous but associated with the classic confluent periventricular T2 intense change of leukoaraiosis (Fazekas ≥2) AND NOT satisfying the diagnostic criteria for multiple sclerosis or with a significant patient history of severe trauma, radiation, drug toxicity, or carbon monoxide poisoning\n\nExclusion Criteria:\n\n* History of AF or atrial flutter\n* Patients with a history of symptoms compatible with an AIS, covert neurological deficits are allowed.\n* Cardiac implantable electronic devices (pacemaker, implantable cardiac defibrillator (ICD), implantable cardiac monitor (ICM))\n* Indication for cardiac implantable electronic device implantation (pacemaker, ICD, ICM)\n* History of or indication for major cardiac surgery or transcutaneous aortic valve implantation\n* Indication for permanent oral anticoagulation\n* Contraindication for permanent oral anticoagulation\n* Projected life expectancy of less than 2 years\n* Active intra- or extracranial high-grade malignancy\n* Patient is already included in another clinical trial that will affect the objectives of this study\n* Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his\u002Fher own wishes correspondingly\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.\n* Known or suspected non-compliance, drug or alcohol abuse","50 Years",{"count":86,"type":20},150,"Arterial Fibrillation (AF) is well-recognized as a cause for cryptogenic Acute Ischemic Stroke (AIS) and is associated with Silent Brain Infarction (SBI). However, the role of AF in the formation of lesions (SBIs) is less well established than its role in AIS and needs clarification.\n\nThe investigators hypothesize that continuous rhythm monitoring will yield a similar incidence of AF diagnosis in patients with SBI as compared to patients with cryptogenic AIS.\n\nThe primary objective is to assess the cumulative incidence of AF diagnosis at 24 months in patients with SBI.",[27,57,89],"Fibrillation",{"date":68,"type":35},{"date":92,"type":35},"2020-09-08",{"date":94,"type":20},"2029-12-31",{"name":74,"class":42},8,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100467624","cerebral-protection-in-transcatheter-left-atrial-appendage-occlusion-100467624","NCT05369195","Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion","Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation","LAAC-SBI","Inclusion Criteria:\n\n1. 18 Years and older\n2. Subject able to provide signed informed consent.\n3. Documented permanent, persistent, or paroxysmal atrial fibrillation\n4. CHA2DS2VASc risk of stroke ≥2\n5. At least one of the following criteria:\n\n   1. Contraindications to the use of anticoagulants,\n   2. HSBLED bleeding risk ≥3\n\nExclusion Criteria:\n\n1. Serious mental diseases, particularly: dementia syndrome of any etiology, schizophrenia,schizoaffective disorders, bipolar disorder\n2. History of ischemic stroke\n3. Chronic abuse of alcohol or any other psychoactive substances except for nicotine\n4. long-term therapy with benzodiazepines\n5. The use of antidepressants in 3 months prior inclusion.\n6. Previous infections of the central nervous system, including neuroborreliosis\n7. Parkinson's disease\n8. Huntington's chorea\n9. Creutzfeld-Jakob disease\n10. Pick's disease\n11. Significant atherosclerosis of the cephalic arteries (\\> 70% LCCA or the brachiocephalic trunk)\n12. Strictures, ectasias, dissection or aneurysms at the exit of the LCCA or the brachiocephalic trunk from the aorta and up to 3 cm above\n13. Advancement of vascular changes in DW MRI of the head, grade 3 on the Fazekas scale\n14. Presence of a thrombus or tumours of a different nature in the left atrium or its ear\n15. Presence of a thrombus in the left ventricle\n16. Left atrial appendage anatomy preventing the use of occluders to close the left atrium appendage\n17. The presence of mechanical heart valve prostheses\n18. The state after the operative closure of the defect in the atrial septum\n19. Condition after closing the defect in the interatrial septum with the use of occluders\n20. Active infective endocarditis\n21. Presence of devices and prostheses that prevent the performance of MRI (pacemakers, clips in the CNS)\n22. Status after oesophagal surgery\n23. Esophageal diverticula\n24. Esophageal varices\\> grade 3\n25. Allergic to contrast agents\n26. A contraindication to use antiplatelet drugs\n27. Diagnosis of neoplastic disease with estimated survival beyond 1 year\n28. Clininally evident hypothyroidism and hyperthyroidism\n29. Klaustrofobia\n30. Pregnancy\n31. AIDS\n32. Participation in other drug research studies\n33. The presence of circumstances or any medical condition the Investigator considers problematic for subject inclusion, or test results that may couse problems to provide reliable, acurate to interpretation results",{"count":106,"type":20},240,"INTERVENTIONAL",[109],"NA","The study aims to assess the effect of the use of neuroprotection in transcutaneous occlusion of the left atrial appendage in patients with atrial fibrillation on the risk of perioperative silent brain ischemia and associated cognitive impairment and depression.",[112,27,113,114],"Atrial Fibrillation","Cognitive Impairment","Depression",[116,117,118,119,120,121],"cerebral protection","left atrial appendage occlusion","atrial fibrillation","silent brain ischemia","cognitive impairment","depression","2023-09-26",{"date":124,"type":35},"2023-09-28",{"date":126,"type":35},"2023-05-26",{"date":128,"type":20},"2026-09",{"name":130,"class":42},"Silesian Centre for Heart Diseases",6]